Soleo Health asks Medicare to expand access to Alzheimer’s treatment
By HME News Staff
Updated 9:07 AM CDT, Thu March 17, 2022
FRISCO, Texas – Soleo Health is urging CMS to allow certain monoclonal antibodies to be used in the treatment of Alzheimer’s Disease. “Patient access to innovative therapy treatments is critical to supporting our aging population, including the recent FDA-approved monoclonal antibody treatment for Alzheimer’s patients,” said Drew Walk, CEO. “We believe new therapeutics for those patients in need could prove extremely beneficial to their well-being and quality of life, while helping manage the overall impact of this devastating disease.” Soleo Health’s position is in response to a recent CMS Decision Memo CAG-00460N limiting coverage of monoclonal antibody treatment, which is approved by the U.S. Food and Drug Administration, for Alzheimer’s Disease. The company also expressed its opposition to a requirement that designates CMS-approved clinical trials be limited to hospital-based outpatient facilities. This requirement creates additional, unnecessary barriers for patients who otherwise could obtain this important therapy, Soleo Health says. Providing broader access to care delivered in the home or at alternate infusion sites is critical for patients who qualify for this therapy, the company says.
Comments